Minor
Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
Enrollment increased: 120 → 144 participants
Tao ZhangPhase 2 NCT07847229 Registry history of NCT07847229 on ClinicalTrials.gov (opens the registry)